Metronidazole validates drugs targeting hypoxic bacteria for improved treatment of tuberculosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 35, 2012, Pages 13890-13891

  Zhang, Ying ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; ISONIAZID; METRONIDAZOLE; MOXIFLOXACIN; OXYGEN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIBACTERIAL ACTIVITY; BACTERIAL CLEARANCE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG DESIGN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTRIC SUCTION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LATENT TUBERCULOSIS; LUNG LAVAGE; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; OXYGEN CONSUMPTION; OXYGEN TENSION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

ANIMALS; LATENT TUBERCULOSIS; METRONIDAZOLE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84865549707     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1211081109     Document Type: Note

References (22)

1. World Health Organization (2008) Global Tuberculosis Control: Surveillance, Planning, Financing (World Health Organization, Geneva), pp 1-294.
2. CDC (2012) Treatment Options for Latent Tuberculosis Infection. Available at http://www.cdc.gov/tb/publications/factsheets/treatment/ LTBItreatmentoptions.htm. Accessed July 5, 2012.
3. Lin PL, et al. (2012) Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci USA 109:14188-14193.
4. Wayne LG, Sramek HA (1994) Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 38:2054-2058. (Pubitemid 24278800)
5. Brooks JV, Furney SK, Orme IM (1999) Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother 43:1285-1288. (Pubitemid 29214765)
6. Via LE, et al. (2008) Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76:2333-2340.
7. Dhillon J, Allen BW, Hu YM, Coates AR, Mitchison DA (1998) Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 2:736-742. (Pubitemid 28429724)
8. Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC (2008) Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis 198:275-283. (Pubitemid 352019294)
9. Hoff DR, et al. (2008) Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 52:4137-4140.
10. Desai CR, et al. (1989) Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J Assoc Physicians India 37:694-697.
11. Wade MM, Zhang Y (2004) Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol 53:769-773. (Pubitemid 39430363)
12. Zhang Y, Mitchison D (2003) The curious characteristics of pyrazinamide: A review. Int J Tuberc Lung Dis 7:6-21. (Pubitemid 36427026)
13. Barry CE, 3rd, et al. (2009) The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 7:845-855.
14. McDermott W (1958) Microbial persistence. Yale J Biol Med 30:257-291.
15. Zhang Y (2007) Advances in the treatment of tuberculosis. Clin Pharmacol Ther 82:595-600.
16. Zhang Y, Yew WW, Barer MR (2012) Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 56:2223-2230.
17. Nuermberger EL, et al. (2004)Moxifloxacin-containing regimens of reduced duration produce a stable cure inmurine tuberculosis. Am J Respir Crit Care Med 170:1131-1134. (Pubitemid 39488628)
18. Dorman SE, et al. (2009) Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180:273-280.
19. Cho SH, et al. (2007) Low-oxygen-recovery assay for high-throughput screening of compounds against non-replicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51:1380-1385. (Pubitemid 46586820)
20. Koul A, et al. (2008) Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 283:25273-25280.
21. Stover CK, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962-966. (Pubitemid 30435054)
22. Nuermberger E, et al. (2008) Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52:1522-1524. (Pubitemid 351522025)